Company: PTHS
Filing Date: 2025-09-29
Form Type: 424B3
Source: 0001753926-25-001561
Chunk: 15

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-09-29
Form: 424B3
Chunk 15
---
 commercializing ZELSUVMI or our other product candidates if and when they are approved.

We have only recently commercially
launched ZELSUVMI and to achieve commercial success for it and any other product candidate for which we may obtain regulatory
approval, we will need to establish an effective sales and marketing organization. We have built a focused sales and marketing
organization to launch ZELSUVMI in the United States, but it may not be large enough to support the market acceptance and revenue
growth of ZELSUVMI that we expect and may need to expand if we receive approval of other product candidates. There are inherent
risks to establishing and maintaining a standalone commercial organization, which is also time-consuming and requires significant
financial resources.

Factors that create risk and may inhibit our efforts to commercialize our products on our own include:

| ● | our                                                                                                 
 inability to recruit, train and retain adequate numbers of effective sales and marketing personnel; |

| ● | the                                                                                     
 inability of sales personnel to obtain access to physicians or educate adequate numbers 
 of physicians on the benefits of prescribing ZELSUVMI or any potential future products; |

| ● | inability                                                       
 to obtain favorable insurance coverage of any approved product; |

| ● | the                                                                                                                                   
 lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies 
 with more extensive product lines; and                                                                                                |

| ● | unforeseen                                                                                   
 costs and expenses associated with creating an independent sales and marketing organization. |

If we are unable to maintain our own sales, marketing and distribution capabilities and are forced to enter into arrangements with, and rely on, third parties to perform these services, our revenue and our profitability, if any, is likely to be lower than if we had maintained such capabilities internally. In addition, in the event we proceed with engaging third parties for sales and marketing services, we may not be successful in entering into arrangements with third parties to sell, market and distribute our products or may be unable to do so on terms that are favorable to it. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish and maintain sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our products.

<div align='center'>9</div>

ZELSUVMI or our product candidates may cause undesirable side effects or have other properties